Internal Medicine, Pulmonary Disease · Burlington, VT
NPI
1710320056
Since 2013
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
111 Colchester Ave
Burlington, VT, 05401
Phone (802) 847-0000
Groups this clinician bills Medicare through
Medicare paid, 2024
$57K
1,445 services
Medicare patients, 2024
429
Average age 74
Drug cost, 2024
$3.6M
1,392 prescriptions
Company payments, 2025
$132
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marta Kokoszynska-Werner was code 94010 (pulmonary function testing), 298 times for 204 patients. In total Marta Kokoszynska-Werner billed 1,445 services in 34 codes, and Medicare paid $57K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-05-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 94010 Pulmonary Function Testing | Facility | 298 | 204 | $5.81 | $1,731 |
| 94729 Pulmonary Function Testing | Facility | 274 | 191 | $6.29 | $1,724 |
| 99214 Office E&M - Established | Facility | 234 | 148 | $69.82 | $16K |
| 94618 Pulmonary Function Testing | Facility | 144 | 116 | $15.86 | $2,284 |
| 99213 Office E&M - Established | Facility | 100 | 82 | $46.74 | $4,674 |
| 99291 Critical Care E&M | Facility | 68 | 54 | $158.83 | $11K |
| 99232 Hospital E&M - Subsequent | Facility | 54 | 38 | $59.32 | $3,203 |
| 94060 Pulmonary Function Testing | Facility | 48 | 48 | $7.14 | $343 |
| 94726 Pulmonary Function Testing | Facility | 34 | 34 | $7.92 | $269 |
| 99204 Office E&M - New | Facility | 27 | 27 | $91.09 | $2,460 |
| 99292 Critical Care E&M | Facility | 20 | 15 | $79.58 | $1,592 |
| 99215 Office E&M - Established | Facility | 20 | 20 | $103.12 | $2,062 |
| 99222 Hospital E&M - Initial | Facility | 19 | 19 | $97.59 | $1,854 |
By year: 2022 $91K for 1,510 services; 2023 $69K for 1,309 services; 2024 $57K for 1,445 services.
Medicare prescription drug claims, 2024
In 2024, the drug Marta Kokoszynska-Werner prescribed most often to Medicare patients was Ofev (Nintedanib Esylate), with 181 prescriptions and refills. In total Marta Kokoszynska-Werner wrote 1,392 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ofev Nintedanib Esylate | 181 | 229 | 26 | $2.9M |
| Prednisone Generic | 145 | 200 | 77 | $1,047 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 91 | 127 | 16 | $80K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 81 | 87 | 43 | $2,658 |
| Pirfenidone Generic | 74 | 76 | 11 | $275K |
| Symbicort Budesonide/Formoterol Fumarate | 72 | 122 | 19 | $27K |
| Mycophenolate Mofetil Generic | 71 | 135 | 13 | $8,754 |
| Spiriva Respimat Tiotropium Bromide | 52 | 64 | Under 11 | $33K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 41 | 49 | Under 11 | $23K |
| Doxycycline Monohydrate Generic | 40 | 40 | 30 | $368 |
| Fluticasone Propionate Generic | 39 | 68 | 13 | $603 |
| Incruse Ellipta Umeclidinium Bromide | 32 | 36 | Under 11 | $13K |
| Ipratropium Bromide Generic | 27 | 50 | Under 11 | $536 |
| Dulera Mometasone/Formoterol | 27 | 43 | Under 11 | $14K |
| Montelukast Sodium Generic | 25 | 59 | Under 11 | $225 |
Brand drugs: 743 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marta Kokoszynska-Werner $132 ($132 in general payments such as food, travel and fees) from 1 company. The largest payer was United Therapeutics Corporation with $132.
| Company | Payments | Amount |
|---|---|---|
| United Therapeutics Corporation UTHR | 1 | $132 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.